3D Medicines Inc.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1244)

VOLUNTARY ANNOUNCEMENT

A PHASE II STUDY PROTOCOL OF ENVAFOLIMAB FOR THE TREATMENT OF dMMR ADVANCED SOLID TUMORS HAS BEEN ALLOWED TO PROCEED BY U.S. FOOD AND DRUG ADMINISTRATION

This announcement is made by 3D Medicines Inc. (the "**Company**", together with its subsidiaries, collectively the "**Group**") on a voluntary basis to update shareholders of the Company and potential investors with the latest business development of the Group.

The board of directors (the "**Board**") of the Company is pleased to announce that on December 30, 2022, the U.S. Food and Drug Administration (the "**FDA**") has formally notified the Company that an investigational new drug application ("**IND**") for the Phase II study for the Company's core product envafolimab for the treatment of mismatch repair deficiency ("**dMMR**") advanced solid tumors may proceed with its proposed clinical study protocol. This IND is a phase II, multiregional, multicenter, single arm study to evaluate the efficacy and safety of envafolimab monotherapy in subjects with dMMR advanced solid tumors. Envafolimab is the core product in the Company's drug pipeline, and will be administrated to the patients subcutaneously every three weeks in this IND study.

About envafolimab

The Company's core product envafolimab is a subcutaneously-injectable PD-L1 antibody and has been approved by the China National Medical Products Administration (國家藥品監督管理局) (the "**NMPA**") for the treatment of previously treated MSI-H/dMMR advanced solid tumors on November 24, 2021. For the year ended December 31, 2021 and for the five months ended May 31, 2022, all of the Group's revenue was generated from the sales of envafolimab, which amounted to RMB60.3 million and RMB161.1 million, respectively.

– In November 2016, we received the IND approval for envafolimab from FDA for solid tumors.

– In February 2017, we launched (i.e. the first patient was enrolled) a first-in-human Phase I clinical trial of envafolimab in subjects with advanced solid tumors in the U.S.

– On January 16, 2020, the FDA granted envafolimab with orphan drug designation for the treatment of advanced biliary tract cancer.

– On June 28, 2021, the FDA granted envafolimab with orphan drug designation for the treatment of soft tissue sarcoma, and this clinical trial was sponsored by our partner TRACON.

– In October 2021, we completed the Phase I clinical trial of envafolimab in subjects with advanced solid tumors in the U.S..

Warning under Rule 18A.05 and Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company may not be able to successfully develop and/or market its core product envafolimab for indications other than the approved indication in previously treated MSI-H/dMMR advanced solid tumors.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
3D Medicines Inc.
Dr. Gong Zhaolong
Chairman of the Board

Hong Kong
December 30, 2022

As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Pai, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.